# An estrogen dependency for Menopause Consultants to examine

> Menopause Consultants examines what a growth-hormone response depends on: endogenous estrogen after menopause and the research around tesamorelin.

**What the rebound depends on**

The consultant’s question is what depends on what. In a postmenopausal experiment, reducing estrogen changed the growth-hormone response.

## Endogenous estrogen after menopause

In [60 healthy postmenopausal women, depleting endogenous estrogen markedly reduced a growth-hormone rebound](https://pubmed.ncbi.nlm.nih.gov/27459535/). The researchers used anastrozole to reduce estrogen and examined the GHRH-mediated release of growth hormone that followed a short intravenous somatostatin infusion. Low levels of endogenous estrogen still mattered to that response.

I expected depletion to tell the entire story. The rebound result shifted the emphasis toward influence that remains. The measured response concerned growth hormone, yet reducing estrogen changed it. The growth-hormone response needs an explanation that includes estrogen.

A consultant’s useful question here is what the response depends on. Sweeping talk of hormonal balance loses the particular dependency this experiment exposed.

> Endogenous means produced within the body; here, the question concerned the estrogen already present.

## A rebound after somatostatin

The sequence gives the [postmenopausal experiment](https://pubmed.ncbi.nlm.nih.gov/27459535/) its interest: a short somatostatin infusion, followed by GHRH-mediated rebound growth-hormone secretion. Estrogen deprivation blunted that rebound. GHRH is growth hormone-releasing hormone, one of the signals regulating growth-hormone release.

I prefer this active test of the system to an inventory of hormone concentrations. The finding gives endogenous estrogen a functional role in the experiment, with a clearly defined response to examine.

[The rebound study](/estrogen-rebound) follows that sequence and places it alongside experiments in men, where the hormonal interventions and responses differed.

## Tesamorelin and GHRH

Tesamorelin is a [stabilised synthetic analogue of GHRH](https://pubmed.ncbi.nlm.nih.gov/22298602/). That relationship makes the physiology relevant to the discussion around the peptide. It also requires some care: the estrogen-depletion study investigated a GHRH-mediated rebound, rather than demonstrating a benefit from tesamorelin in menopause.

The [tesamorelin page](/tesamorelin) follows the molecule's protective modification and a small hormone study in healthy men. The [cognition page](/cognition) turns to a different question altogether: whether a change in this hormonal system translates into a measured cognitive benefit. The chemical modification and the cognitive outcome each have to earn their place.

## Essay topics

- [Estrogen and the rebound](/estrogen-rebound): the postmenopausal experiment and the influence of hormonal context.
- [Tesamorelin's modification](/tesamorelin): protection against enzyme breakdown, followed by human hormone measurements.
- [Cognitive outcomes](/cognition): an executive-function result in older adults and a separate trial in people with HIV.

The articles are gathered on the [reading list](/references). [About](/about) explains why this collection is called Menopause Consultants.

---

At Menopause Consultants I examine what hormonal responses depend on in published research; this essay site is no consulting business, and its discussion provides no medical advice.